Mark Talamonti to Antineoplastic Agents
This is a "connection" page, showing publications Mark Talamonti has written about Antineoplastic Agents.
Connection Strength
0.136
-
Perioperative chemotherapy is associated with a survival advantage in early stage adenocarcinoma of the pancreatic head. Surgery. 2016 09; 160(3):714-24.
Score: 0.061
-
Neoadjuvant therapy for pancreatic cancer: a current review. J Surg Oncol. 2010 Mar 15; 101(4):315-20.
Score: 0.039
-
A novel anti-pancreatic cancer agent, LY293111. Anticancer Drugs. 2005 Jun; 16(5):467-73.
Score: 0.028
-
A novel peptide sansalvamide analogue inhibits pancreatic cancer cell growth through G0/G1 cell-cycle arrest. Biochem Biophys Res Commun. 2006 Feb 24; 340(4):1224-8.
Score: 0.007